secreted by the pineal gland at night, has long been suspected to be involved in human sleep regulation. Early studies reported sleep-inducing effects (1) and increased sedation (8) after exogenous melatonin administration in pharmacological doses. There have even been suggestions that the pineal is a "tranquilizing" organ (32). On the basis of these and more recent studies (17, 18, 35, 39) , the "hypnotic" effects have been hypothesized to be an integral part of the natural physiological role of melatonin, although whether melatonin should be considered in these terms at all is questionable (36). In contrast to the hyperthermic effect of bright light (3, 5, 6, 33) , orally administered melatonin in doses ranging from 0.3 to 80 mg decreases body temperature (12, 17, IS) . This suggests that the sleep-inducing effect of melatonin may be mediated through lowering of core body temperature (11).
Both animal (31) and human studies (26, 38) document that melatonin is capable of inducing phase shifts of the circadian system, the direction of which is dependent on circadian phase of administration.
In humans, only one preliminary study so far has investigated melatonin's entrainment capacity in free-running conditions (28). Nevertheless, melatonin's entrainment power is not yet validated. More is known of its usefulness in ameliorating sleep disturbances associated with circadian dysfunction [in blind people, delayed sleep phase syndrome, and jet lag (for an overview, see Ref.
2)]. Therefore, taken together, there is strong evidence that acute administration of melatonin augments sleep propensity and phase shifts the circadian pacemaker. Because sleep consolidation and sleep structure are dependent on an appropriate phase relationship between the sleep-wake cycle and the endogenous circadian pacemaker (14), the interpretation of studies investigating the effects of melatonin on sleep parameters is difficult (for a review, see Ref. 11 ). In addition, the effects of melatonin on the sleep electroencephalogram (EEG) are not yet well documented. The observed changes in REM sleep (22) are more consistent with the phase-shifting effects of melatonin, whereas changes in the sleep EEG spectra seen after daytime administration are likely to be related to an acute hypnotic and possibly noncircadian action of melatonin (15, 35) . Dawson and Encel (11) suggest that the improvement in sleep after evening melatonin administration (later than 2100) may reflect the hypnotic effects, whereas afternoon administration is more likely to be related to circadian effects. Therefore, the relationship between the timing of exogenous melatonin application and sleep, and whether or not endogenous melatonin is being secreted, is of crucial importance when designing melatonin studies.
The aim of the present study was to use an experimental strategy that is able to distinguish between circadian and noncircadian effects of exogenous melatonin and its repercussions on sleep architecture and EEG power density. Second, we wanted to compare the effects of melatonin with the novel melatonin agonist S-20098 (37) . S-20098 has been fully characterized to be assessed in human studies. S-20098 binds to the sheep pars tuberalis melatonin receptor with a dissociation constant of 8.10-11 M. Its effect on sleep and circadian rhythms has been assessed in in vivo animal models (27, 30, 34) .
METHODS

Subjects
Eight male students (age 23-32 yr) were paid to participate in the study to which they gave their informed consent. wk between April and July 1994. The subjects were not informed on which day they would receive the active substance.
Subjects reported at 1500 to the chronobiology laboratory where the electrodes were attached. They remained supine and awake in bed in a sound-attenuated chronobiology room (temperature 22°C humidity 60%, light ~10 lx) from 1600 to 2300. During this 7-h period a "mini"-constant routine (mini-CR) was carried out, with protocol and procedure adapted from others (9) as used in our previous studies. Isocaloric meals (sandwiches) and water were given every hour to meet energy requirements.
Saliva melatonin samples were collected in hourly intervals.
Subjective sleepiness and mood ratings were assessed on visual analog scales every 30 min. One hour before and after the pill intake, a 5-min waking EEG was recorded.
Results on subjective sleepiness ratings and waking EEG power density have been recently reported (7). The subjects were cared for by trained personnel and remained awake until 2300 without information about time of day. This mini-CR represents a standardized procedure that permits reduction of masking effects on circadian parameters measured, as well as no postural change at subsequent sleep onset. The sleep period was scheduled from 2300 to 0700 during which the lights were off. The pill was administered at 1800,5 h before anticipated sleep onset. Hz and into l-Hz bins in the range of 5. 25-25.0 Hz. In connection with the on-line calculation of the 4-s spectra, a time mark was written on the polygraph paper at 20-s intervals to enable optimal synchronization of the sleep scoring with the spectral data. Every five consecutive 4-s EEG spectra were collapsed into 20-s spectra off-line. In this averaging procedure, 4-s epochs contaminated with artifacts were omitted automatically by an artifact detection routine.
The sleep EEGs were scored manually according to established criteria (29) every 20 s and synchronized with the power spectra. NREM-REM sleep cycles were defined according to published criteria (20), with the following exception: for the last cycle analyzed (cycle 4) no minimum of REM sleep duration following on NREM sleep was required.
For cycles 2-4, the first 20-s epoch after the last REM sleep epoch was defined as the onset of the cycle.
Statistics
The SAS statistical package (SAS Institute, Cary, NC) was used. Sleep stages were expressed as percent of total sleep time or percent of NREM sleep-REM sleep cycle duration. For some sleep parameters (e.g., sleep latency, REM sleep latency) and EEG power density, data were log transformed to meet the requirements of a normal distribution. Data were first averaged per subject so that all subjects would contribute with equal weight, and then the data were averaged over all subjects (n = 8).
Statistical significance between the four groups (placebo, Mel, S5, and SlOO) was assessed with two-way analyses of variance (ANOVA) for repeated measures, with the factors "group" and "night," or one-way ANOVAs for repeated measures with the factor "group." All P values derived from repeated-measure ANOVAs were based on Huynh-Feldt's (H-F) corrected degrees of freedom, but the original degrees of freedom are reported.
When the F ratio proved significant, Duncan's multiple-range post hoc tests and linear contrasts with H-F statistics were applied to locate significant differences between the means. Statistics on the time course of accumulated sleep stages were performed by the nonparametric Wilcoxon's signed-rank test.
RESULTS
Sleep Stages
Entire sleep episode. Table 1 summarizes the sleep parameters calculated over the entire sleep episode for the pretreatment night, treatment night (TN), and posttreatment night (PTN) of the placebo, Mel, S5, and SlOO group. The six placebo nights (all pretreatment nights of each group and the TNs and PTNs of the placebo group) were tested for their homogeneity. First, to assess significant changes in the course of the three consecutive nights in the placebo condition, only the three nights (pretreatment night, TN, and PTN) of the placebo group were analyzed by a one-way ANOVA with the factor night. For none of the sleep parameters listed in Table 1 12.0 t 2.0 11.9 + 1.9 11.7 +. 1.9 12.6 + 2.2 11.8 + 1.9 13.2 k 2.5 13.2 5 2.4 13.6 t 2.6 22.12 1.5 25.4 + 1.5*-j-$ 24.0 t l.l*$ 24.5 ? 1.2*"c$ found (P > 0.2). Second, to assess significant changes in the course of the experimental protocol (week effect) all pretreatment nights were assorted according to their timing (week 1 through week 4). Aone-way ANOVAwith the factor week revealed no significant changes for any sleep parameters, except for the variable sleep latency. Post hoc comparison between the first week and the last week revealed a trend to shorter sleep latencies (P = 0.07). Third, 11 a six placebo nights were compared using a one-way ANOVA with the factor night. No significant changes were found for any of the sleep variables (P > 0.2). Because none of the sleep variables calculated for the entire sleep episode differed significantly between the six placebo nights, corresponding values of these six placebo nights were averaged per subject ("pooled placebo," Table 1) .
For each sleep parameter a two-way ANOVA for repeated measures with the factors group and night was performed (Table 2) . Asignificant interaction factor group x night was found for REM sleep, and a tendency was observed for arousals within sleep. The P values for the factor night yielded significance for REM sleep, stage 2, sleep latency, and REM sleep latency. In addition, the factor group was significant for stage 2. Post hoc comparisons were performed on the parameter REM sleep, for which a significant interaction group X night was found. REM sleep in the TN was significantly enhanced by all treatments (Mel, S5, SlOO) in comparison with the corresponding pretreatment nights and with the pooled placebo. Comparisons with the TN of the placebo revealed a significant increase in REM sleep for Mel and a tendency for SlOO. REM sleep in the PTN was still significantly enhanced in the SlOO group when compared with the pooled placebo.
NREM-REM sleep cycles. To inspect the temporal evolution of different sleep parameters more closely, NREM-REM sleep cycles across each sleep episode were defined according to the above-mentioned criteria.
A two-way ANOVA for repeated measures with the factors group and night was performed for each cycle separately. The interaction factor group X night was significant for REM sleep in the first cycle (F642 = 2.8, P < 0.03), whereas no significant interaction factor was found in cycles 2 and 3. REM sleep in the first cycle of the TN was significantly longer in the Mel and SlOO than in the placebo group. The comparisons of Mel, SlOO, and S5 vs. the corresponding pretreatment nights and the pooled placebo value were also significant ( Table 3) .
In the TN, a two-way ANOVA for repeated measures revealed significant changes in %REM sleep (percent of cycle duration) and REM sleep episode duration for the factors group and cycle (%REM sleep: group F, 21 = 3.89, P < 0.03; cycle F 2,14 = 7.22, P < 0.008; REM sleep episode duration: group FS,21 = 6.62, P < 0.003; cycle F 2,14 = 25.2, P < 0.0001); because the REM sleep episode in cycle 4 was not followed by a further NREM sleep episode in all subjects, the ANOVA was limited to three cycles (Fig. 1) .
During the PTN, the above-mentioned effects disappeared. No significant differences were found for any of the sleep parameters.
Accumulation of REM sleep and the combined stages: wakefulness, stage 1, and movement time. lated and plotted in lo-min intervals. For statistical analysis, the nights were divided into four 2-h intervals. REM sleep and the sum of stages 0 and 1 and MT were accumulated within each single 2-h interval. A two-way ANOVA for repeated measures, with the factors group and night was performed for each interval separately, The interaction factor group X night was significant for the variable REM sleep (F6 42 = 2.5, P < 0.04) in the first 2-h interval, whereas for'the intervals 2, 3, and 4 no significant interaction was found. Post hoc comparisons in the first 2-h interval revealed a significant REM sleep augmentation for the Mel and SlOO group vs. the placebo group, the pooled placebo, and the pretreatment value. For the arousal measure (stages 0 and 1 and MT), a tendency (F642 = 2.3, P = 0.07) in the interaction factor was found'when adding the values of 2-h intervals 3 and 4. Figure 2 , A and B, shows that the REM sleep-curves for the Mel and SlOO group separated 2 h after lights off from the pooled placebo curve on the TN but not on the PTN. The REM sleep accumulation curve in TN of the S5 group also dissociated from placebo 2 h after lights off (data not shown). REM sleep accumulated faster after Mel, S5, and SlOO. In contrast, the stages 0 + 1 + MT-curves were identical in the TN of placebo, melatonin, and SlOO, but differed in the PTN, where they -. significantly dissociated from placebo after 7 h in the Mel group and after 5 h in the SlOO group. The combined stages 0 and 1 and MT accumulated faster in the second night after Mel or SlOO. The accumulation in TN and PTN of the S5 group was not significantly different from placebo (data not shown).
Correlation between the first REM sleep episode duration and core body temperature. To test whether there was a relationship between the prolongation of the first REM sleep episode and circadian timing, the mean first REM sleep duration was correlated with the midrange crossing time of core body temperature decline (24,25) (Fig. 3) . Data from all experimental days were included in the analysis. The negative correlation between the two variables was significant (r = 0.79; P < 0.0025; n = 12; product-moment correlation), i.e., the earlier the temperature phase, the longer the duration of the first REM sleep episode.
EEG Power Density
Entire sleep episode. EEG power density during . NREM sleep is illustrated for both TN and PTN (Fig. 4) . A one-way ANOVA for repeated measures revealed no significant changes for the factor group in any of the frequency bins (0.25-20 Hz), neither for NREM sleep nor REM sleep on either night (REM sleep data not shown). In addition, analyses limited to shorter time intervals (e.g., first one-third of the night or first hour of the night, etc.) revealed no consistent trends or significant changes in comparison to placebo (data not shown).
Dynamics of slow-wave activity in NREM sleep-REM sleep cycles. For a more detailed visualization of the time course of slow-wave activity @WA), defined as EEG newer density in the frequency range of 0.75-4.5 Hz, each NREM sleep episode was subdivided into 20 equal parts (percentiles) and each REM sleep episode into four equal parts (Fig. 5) . SWA exhibited the well-known buildup in the first part of NREM sleep episodes and a rapid decline before REM sleep episodes. Also, the typical declining trend of SWA over successive NREM sleep episodes was present in all four groups.
On the TN (Fig. 5A) , SWA did not differ significantly from placebo in any of the treatment groups in any of the percentiles (l-way ANOVA for repeated measures factor group, P > 0.05). A similar negative result was obtained in the PTN (Fig. 5.B) . However in TN, due to the prolongation of the first REM sleep episode, the initiation of the following NREM sleep and REM sleep episodes was delayed after Mel and SlOO. To quantify the magnitude of this delay, the time course of SWA of the placebo (SWAplacebo) and treatment groups was analyzed by cross-correlation analysis. A mean cross-correlation coefficient was calculated separately for the eight subjects between SWAplaCebO and SWA of all treatment groups. For the determination of time lag with the highest absolute correlation coefficient, SWA data in 2-min intervals after the first NREM sleep episode were used. The maxima of crosscorrelation curves of Mel, S5, and SlOO were at positive lags, indicating a delay with respect to SWAplacebo. The mean maximal cross-correlations were at time lags of 14 t 2.7 min for Mel, 14 t: 2.9 min for SlOO, and 5. advances in core body temperature of -1 h had no effect on REM sleep (13, 19) . Because the amount of REM sleep is also likely to be dependent on the actual level of core body temperature, the REM sleep increase in the TN may also result from the acute hypothermic effect of melatonin and the melatonin agonist.
A clear indication for a persistent phase shift on the PTN after melatonin or agonist administration is in the early rise of the accumulated stages of wakefulness, stage 1, and MT, which together reflect the wake-up tendency during the course of a night. An earlier increase in the wake-up threshold is considered to be a reflection of a phase advance. For example, a phase advance induced by morning bright light not only reduced sleep duration (16) NREM-REM sleep cycles in the PTN (Fig. 5B ) still appeared delayed, no significant differences were found.
DISCUSSION
Sleep Stages
The present study clearly shows that the acute phase advance of the circadian body temperature rhythm induced by melatonin or the melatonin agonist S-20098 (24, 25) is reflected in a selective modification of sleep stages. The shift to a long first REM sleep episode resembles the pattern seen when entrained subjects free run in temporal isolation (40). Under these circumstances the minimum of the body temperature rhythm advances to the beginning of the major sleep episode. The prolongation of the first REM sleep episode correlated with the midrange crossing time of body temperature decline. Because the timing of REM sleep is coupled to the circadian rhythm of core body temperature (10) 
Hypnotic Effect of Melatonin and S-20098
Wake EEG data objectively document the acute soporific effect of melatonin and its agonist that is subjectively noted as increased fatigue (7). Although subjects felt more tired after melatonin and the melatonin agonist, sleep latency, a common measure of hypnotic activity, was shorter only after the higher dose of S-20098. A possible explanation for this is that, in contrast to a previous study that describes shorter sleep latencies after low melatonin doses administered in the late evening (39), the time gap between pill ingestion and lights out in our study was 5 h. Nevertheless, the average salivary melatonin levels at 2300 after exogenous melatonin administration were still seven times higher than the endogenous nocturnal rise (7) and still sleep latency was not significantly reduced. In addition, the usual problem of demonstrating a shortened sleep latency in subjects specifically screened for being good sleepers may also play a role. However, there was a clear soporific effect of melatonin and its agonist, both enhancing theta/alpha frequency activity in the waking EEG and increasing self-reported sleepiness (Ref. 7; unpublished data Apart from the acute effect induced by melatonin and S-20098, the changed phase relationships between sleep and the circadian system had no effect on the mean EEG power density and the time course of EEG power density.
It is known that changes in phase relationships of this extent (~1 h) have no (13) or minor effects (5) on EEG power density A recent study has reported circadian modulation of sigma activity (12.75-15.0 Hz) with maximum activity at habitual bedtime (14). Although NREM sleep stage 2 was reduced by melatonin and S-20098 in our study, there was no decrease in sigma activity, which is associated with the highest density of sleep spindles within NREM sleep. Nevertheless, compared with placebo, sigma activity at the beginning of the sleep episode of the TN tended to be reduced after melatonin and S-20098 (P < 0.1; data not shown). A more detailed analysis of spindle activity and larger phase shifts are needed to elucidate whether melatonin is also able to shift the rhythm of sigma activity.
The changes in REM sleep and the earlier termination of sleep may be considered in association with the phase advance seen in several circadian markers in this study (24, 25 
